+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Opportunities for the treatment of inflammation in cardiovascular disease

Opportunities for the treatment of inflammation in cardiovascular disease

Expert Opinion on PharmacoTherapy 2(11): 1751-1763

Atherosclerosis, and the clinical presentation of atherosclerosis, both have their basic pathogenesis in inflammatory mechanisms. The use of mouse models of atherosclerosis has emphasised the importance of inflammation in atherogenesis and the use of serum markers of inflammation in epidemiological studies has shown the importance of inflammatory status in determining the presentation of atherosclerotic disease. Therapeutic opportunities will arise from the manipulation of these inflammatory mechanisms. Proof of this principle has been shown with the use of aspirin and statin drugs as well as the emerging roles for peroxisome proliferator-activated receptor (PPAR) agonists. It is likely that both refinement of existing anti-inflammatory agents and the identification of new inflammatory mechanisms will afford real opportunities for the treatment of atherosclerotic cardiovascular disease.

(PDF emailed within 0-6 h: $19.90)

Accession: 046870104

Download citation: RISBibTeXText

PMID: 11825314

DOI: 10.1517/14656566.2.11.1751

Related references

Prevention of cardiovascular disease guided by total risk estimations--challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy. European Journal of Preventive Cardiology 19(6): 1454-1464, 2013

Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. American Journal of Cardiology 101(10a): 58d-68d, 2008

Mechanistic insights into the link between inflammation and cardiovascular disease: rheumatoid arthritis as a human model of inflammation. Circulation. Cardiovascular Imaging 7(4): 575-577, 2014

Combination of Azathioprine and Aminosalicylate Treatment Prevent Risk of Cardiovascular Disease in Women with Ulcerative Colitis by Reducing Inflammation. Medical Science Monitor 21(): 2305-2315, 2016

C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabetic Medicine 21(8): 810-817, 2004

Leukocytes Link Local and Systemic Inflammation in Ischemic Cardiovascular Disease: An Expanded "Cardiovascular Continuum". Journal of the American College of Cardiology 67(9): 1091-1103, 2016

Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. European Heart Journal 36(8): 482-49c, 2015

Composition and method containing products extracted from Commiphora sp for prevention and treatment of abnormal cell growth and proliferation in inflammation, neoplasia and cardiovascular disease. Official Gazette of the United States Patent & Trademark Office Patents 1261(3), Aug 20, 2002

Cardiovascular pathophysiology in chronic kidney disease: opportunities to transition from disease to health. Annals of Global Health 80(1): 69-76, 2015

Forum on cardiovascular disease epidemiology. Introduction: opportunities for primary prevention of coronary artery disease. Preventive Medicine 4(4): 482-490, 1975

Immune activation and inflammation in patients with cardiovascular disease are associated with higher phenylalanine to tyrosine ratios: the ludwigshafen risk and cardiovascular health study. Journal of Amino Acids 2014: 783730-783730, 2014

CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: laboratory tests available to assess inflammation--performance and standardization: a background paper. Circulation 110(25): E572-E576, 2004

From the Centers for Disease Control and Prevention. Missed opportunities in preventive counseling for cardiovascular disease--United States, 1995. JAMA 279(10): 741-742, 1998

Inflammation and biomarkers in vascular disease: emerging insights and opportunities. Canadian Journal of Cardiology 28(6): 616-618, 2013